ImmunoPrecise Antibodies Ltd. (IPA)

ImmunoPrecise Antibodies Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Year	2023	2022	2021	2020	2019
Net Income	-26.56	-16.71	-7.34	-4.95	-7.62
Depreciation & Amortization	6.72	3.85	4.06	4.31	3.19
Share-Based Compensation	1.94	3.08	2.75	0.74	1.11
Other Operating Activities	-1.93	-0.15	-0.07	-1.49	0.11
Operating Cash Flow	-19.83	-9.92	-0.6	-1.39	-3.21
Capital Expenditures	-1.5	-1.26	-1.43	-0.58	-0.65
Acquisitions	-0.51	-3.69	-1.03	-1.01	-1.56
Other Investing Activities	0.04	-0.26	-	-	-
Investing Cash Flow	-1.97	-5.21	-2.46	-1.58	-2.2
Share Issuance / Repurchase	0.72	3.85	44.15	0.49	9.84
Debt Issued / Paid	-1.34	-0.96	-0.77	-0.32	-0.2
Other Financing Activities	-	-0.01	-	-	-0.29
Financing Cash Flow	-0.62	2.88	43.38	0.17	9.35
Net Cash Flow	-22.42	-12.25	40.32	-2.8	3.94
Free Cash Flow	-21.33	-11.18	-2.03	-1.97	-3.85
Free Cash Flow Margin	-103.21%	-57.73%	-11.32%	-13.99%	-35.25%
Free Cash Flow Per Share	-0.86	-0.57	-0.12	-0.14	-0.31

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).